Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 912 KB, PDF-dokument

  • Johannes M. Schwenke
  • Christian W. Thorball
  • Isabella C. Schoepf
  • Ryom, Lene
  • B. Hasse
  • Olivier Lamy
  • Alexandra Calmy
  • G. Wandeler
  • C. Marzolini
  • Christian R. Kahlert
  • Enos Bernasconi
  • R. D. Kouyos
  • H. F. Günthard
  • Bruno Ledergerber
  • Jacques Fellay
  • Felix Burkhalter
  • P. Tarr
  • Swiss HIV Cohort Study (SHCS)
Background
Bone mineral density (BMD) loss may be accelerated in people with HIV (PLWH). It is unknown whether a polygenic risk score (PRS) is associated with low BMD in PLWH.

Methods
Swiss HIV Cohort Study participants of self-reported European descent underwent ≥2 per-protocol dual x-ray absorptiometry (DXA) measurements ≥2 years apart (2011–2020). Univariable and multivariable odds ratios (ORs) for DXA-defined osteoporosis were based on traditional and HIV-related risk factors and a genome-wide PRS built from 9413 single-nucleotide polymorphisms associated with low BMD in the general population. Controls were free from osteoporosis/osteopenia on all DXA measurements.

Results
We included 438 participants: 149 with osteoporosis and 289 controls (median age, 53 years; 82% male, 95% with suppressed HIV RNA). Participants with unfavorable osteoporosis PRS (top vs bottom quintile) had univariable and multivariable-adjusted osteoporosis ORs of 4.76 (95% CI, 2.34–9.67) and 4.13 (1.86–9.18), respectively. For comparison, hepatitis C seropositivity, 5-year tenofovir disoproxil fumarate exposure, and parent history of hip fracture yielded univariable osteoporosis ORs of 2.26 (1.37–3.74), 1.84 (1.40–2.43), and 1.54 (0.82–2.9).

Conclusions
In PLWH in Switzerland, osteoporosis was independently associated with a BMD-associated PRS after adjustment for established risk factors, including exposure to tenofovir disoproxil fumarate.
OriginalsprogEngelsk
TidsskriftJournal of Infectious Diseases
Vol/bind228
Udgave nummer6
Sider (fra-til)742-750
Antal sider9
ISSN0022-1899
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Financial support. This study has been financed within the framework of the SHCS, supported by the Swiss National Science Foundation (grant #201369), SHCS project #859, and the SHCS Research Foundation. The data are gathered by the 5 Swiss university hospitals, 2 cantonal hospitals, 15 affiliated hospitals, and 36 private physicians (listed in http://www.shcs.ch/180-health-care-providers ). Funding to pay the Open Access publication charges for this article was provided by University of Basel.

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

ID: 397033385